Eiger BioPharmaceuticals, Inc. (EIGR)
(Delayed Data from NSDQ)
$10.50 USD
-0.22 (-2.05%)
Updated May 3, 2019 04:00 PM ET
After-Market: $10.53 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Eiger BioPharmaceuticals, Inc. [EIGR]
Reports for Purchase
Showing records 81 - 100 ( 112 total )
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are placing shares of EIGR Under Review, and transferring coverage to ROTH Capital Research due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q''17 Inline; All Four Pipeline Programs Have Key 2018 Events; Reit Buy
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2020 NDA Filing on Track; Pos Interim Results for PEG-IFN-Lambda in HDV
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Buy and $35 price target
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Ka-Ching! Mydicar Deal Brings-In Non-Dilutive Revenue.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Assuming Coverage at OUTPERFORM in Front of Multiple Potential Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Analyst Day Lays out Path Towards HDV Registration and an Overview of Exendin (9-39); Reiterate OUTPERFORM and Adjusting PT to $28
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Lonafarnib Data Set Stage for Pivotal Development; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Eiger Reports 3Q16 Ahead of HDV Data at AASLD; Reiterate OUTPERFORM and Adjusting Price Target to $34
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 7
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D